ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate | 121138-82-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate
• 英文别名: ethyl 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidine-1-carboxylate；ethyl 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinecarboxylate；ethyl 4-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenylidene)piperidine-1-carboxylate
• CAS: 121138-82-7
• 化学式: C₂₃H₂₃NO₂
• 分子量: 345.441
• InChiKey: KGHBMYXZAFEZSU-UHFFFAOYSA-N

物化性质

• 熔点：
  116 °C(Solv: methanol (67-56-1))
• 沸点：
  499.5±45.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 塞庚啶
  参考文献：
  名称：

  低价钛新合成赛庚啶和相关化合物

  摘要：

  描述了一种基于两种合适的酮与低价钛的不对称二羰基偶联制备联苯亚甲基哌啶，赛庚啶和相关化合物的简单方法。

  DOI：

  10.1016/s0040-4020(01)89809-4
• 作为产物：
  描述：

  塞庚啶 、 氯甲酸乙酯 以 甲苯 为溶剂， 反应 5.0h， 以94%的产率得到ethyl 4-(5H-dibenzocyclohepten-5-ylidene)-1-piperidinecarboxylate
  参考文献：
  名称：

  Amphoteric Drugs. II. Synthesis and Antiallergic Activity of (4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)piperidino)alkanoic Acid Derivatives and Related Compounds.

  摘要：

  描述了一种将经典三环抗组胺药物转化为具有相同效力的无镇静抗过敏剂的简单方法，适用于大鼠和豚鼠。合成了一系列[4-(5H-二苯并[a, d]环庚烯-5-亚基)-哌啶基]烷酸衍生物（6a）及相关化合物（6b-f），并与相应的N-甲基衍生物（2a-f）比较了其抗过敏和抗组胺活性以及对中枢神经系统（CNS）的影响。N-烷基羧酸（6a-f）在大鼠48小时同源被动皮肤过敏反应（PCA）中的抑制作用强于2a-f，并且在小鼠六氟巴比妥诱导麻醉的睡眠时间延长方面效果不如2a-f。进一步修饰的结果发现，在两性化合物的三环系统中心环中引入氧原子增强了它们的抗过敏和抗组胺活性。3-[4-(6H-二苯并[b, e]氧烯-11-亚基)哌啶基]丙酸（6c）在大鼠48小时同源PCA中表现出强的抑制作用（ED50=0.067mg/kg，口服），以及在麻醉豚鼠中对组胺诱导的支气管收缩的抑制作用（ED50=0.0085mg/kg，口服），因此是一个有前景的抗过敏剂候选物。

  DOI：

  10.1248/cpb.42.2285

文献信息

• HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST
  申请人：Okada Makoto

  公开号：US20130085127A1

  公开（公告）日：2013-04-04

  A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R 1 is a carbonyl group or an alkylene group; R 2a and R 2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R 1 is an alkylene group which may have a substituent.

  提供一种作为抗过敏剂使用的杂环化合物。所述化合物由以下式（1）或其盐表示：其中环A是同环或杂环；环B是一个杂环，其中包含G和氮原子N作为其组成原子，其中G是CH或N；R1是一个羰基或一个烷基基团；R2a和R2b是烷基基团、环烷基基团、芳基团或杂环基团；X是一个氧原子或硫原子；Z是一个羟基、烷氧基、环烷氧基、芳氧基、芳基氧基、氨基或N-取代氨基；n为0或1；但条件是当环A为苯环或环B为哌嗪环时，R1是可能有取代基的烷基基团。
• 시프로헵타딘 유도체, 이의 제조방법 및 이를 포함하는 식욕 촉진용 조성물
  申请人：KNU-Industry Cooperation Foundation 강원대학교산학협력단(220040088571) BRN ▼221-82-10213

  公开号：KR20200083094A

  公开（公告）日：2020-07-08

  본 발명은 시프로헵타딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 포유동물의 식욕 촉진용 조성물을 제공한다. 본 발명의 시프로헵타딘 유도체는 mHypoE 세포주에서 시프로헵타딘과 유사하거나 더 낮은 AgRP 발현량을 나타내어 우수한 식욕 촉진 효과를 나타내고, 육계 및 자돈에서 우수한 증체 효과를 나타내므로, 본 발명의 시프로헵타딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 포유동물의 식욕 촉진용 조성물은 동물 의약품 및 사료 첨가제 분야에서 유용하게 사용될 수 있다.

  本发明提供了一种促进哺乳动物食欲的组合物，其中包括siprotentadin衍生物或其药学上可接受的盐，以及其制备方法。本发明的siprotentadin衍生物在mHypoE细胞株中表现出与siprotentadin相似或更低的AgRP表达水平，显示出优越的食欲促进效果，并且在家禽和猪中显示出优越的生长促进效果，因此，本发明的siprotentadin衍生物或其药学上可接受的盐、其制备方法以及包含它们的促进哺乳动物食欲的组合物在动物药品和饲料添加剂领域中可以得到有益的应用。
• Piperidine derivatives and pharmaceutical compositions comprising the
  申请人：Hokuriku Pharmaceutical Co., Ltd.

  公开号：US05095022A1

  公开（公告）日：1992-03-10

  A piperidine derivative represented by the following general formula (I): ##STR1## wherein R represents a hydrogen atom or a lower alkyl group; X represents --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, or --CH.sub.2 O--; Y represents an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an --A--O--B-- group wherein A and B are the same or different and each independently represented an alkylene group having 1 to 3 carbon atoms which may be optionally substituted with a lower alkyl group is disclosed. Also disclosed are a pharmacologically acceptable salt of a compound of formula (I), a method for preparation of a compound of formula (I), an antihistaminic and antiallergic agent comprising a compound of formula (I), a pharmaceutical composition comprising a compound of formula (I), and a method for the treatment of an allergic disease by administering a compound of formula (I).

  以下是一种由下列通式(I)表示的哌啶衍生物：##STR1## 其中R代表氢原子或较低的烷基基团；X代表--CH.dbd.CH--，--CH.sub.2 CH.sub.2 --或--CH.sub.2 O--；Y代表具有1到5个碳原子的烷基基团，该基团可以选择性地用较低的烷基基团取代，或者Y代表--A--O--B--基团，其中A和B相同或不同，且每个都独立地表示具有1到3个碳原子的烷基基团，该基团可以选择性地用较低的烷基基团取代。还公开了通式(I)化合物的药理上可接受的盐、一种制备通式(I)化合物的方法、包括通式(I)化合物的抗组胺和抗过敏剂、包括通式(I)化合物的药物组合物，以及通过给予通式(I)化合物治疗过敏疾病的方法。
• Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
  申请人：HOKURIKU PHARMACEUTICAL CO., LTD.

  公开号：EP0406739A2

  公开（公告）日：1991-01-09

  A piperidine derivative represented by the following general formula (I): wherein R represents a hydrogen atom or a lower alkyl group; X represent -CH=CH-, -CH₂CH₂-, or -CH₂O-; Y represent an alkylene group having 1 to 5 carbon atoms which may be optionally substituted with a lower alkyl group, or Y represents an -A-O-B- group wherein A and B are the same or different and each independently represents and alkylene group having 1 to 3 carbon atoms which may be optionally substituted with a lower alkyl group is disclosed. Also disclosed are a pharmacologically acceptable salt of a compound of formula (I), a method for preparation of a compound of formula (I), an antihistaminic and antiallergic agent comprising a compound of formula (I), and a method for the treatment of an allergic disease by administering a compound of formula (I).

  由以下通式 (I) 代表的哌啶衍生物： 其中 R 代表氢原子或低级烷基；X 代表 -CH＝CH-、-CH₂CH₂- 或 -CH₂O-；Y 代表具有 1 至 5 个碳原子的亚烷基，可任选被低级烷基取代，或 Y 代表-A-O-B-基团，其中 A 和 B 相同或不同，且各自独立地代表具有 1 至 3 个碳原子的亚烷基，可任选被低级烷基取代。还公开了式(I)化合物的药理学上可接受的盐、式(I)化合物的制备方法、包含式(I)化合物的抗组胺剂和抗过敏剂，以及通过施用式(I)化合物治疗过敏性疾病的方法。
• Loratadine analogues as MAGL inhibitors
  作者：Jayendra Z. Patel、Stephen Ahenkorah、Miia Vaara、Marek Staszewski、Yahaya Adams、Tuomo Laitinen、Dina Navia-Paldanius、Teija Parkkari、Juha R. Savinainen、Krzysztof Walczyński、Jarmo T. Laitinen、Tapio J. Nevalainen

  DOI：10.1016/j.bmcl.2015.02.037

  日期：2015.4

  Compound 12a (JZP-361) acted as a potent and reversible inhibitor of human recombinant MAGL (hMAGL, IC50 = 46 nM), and was found to have almost 150-fold higher selectivity over human recombinant fatty acid amide hydrolase (hFAAH, IC50 = 7.24 mu M) and 35-fold higher selectivity over human alpha/beta-hydrolase-6 (hABHD6, IC50 = 1.79 mu M). Additionally, compound 12a retained H-1 antagonistic affinity (pA(2) = 6.81) but did not show cannabinoid receptor activity, when tested at concentrations <= 10 mu M. Hence, compound 12a represents a novel dual-acting pharmacological tool possessing both MAGL-inhibitory and antihistaminergic activities. (C) 2015 Elsevier Ltd. All rights reserved.